NeuroPace (NeuroPace) Accounts Receivable : $11.63 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NeuroPace Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. NeuroPace's accounts receivables for the quarter that ended in Mar. 2024 was $11.63 Mil.

Accounts receivable can be measured by Days Sales Outstanding. NeuroPace's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 58.56.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. NeuroPace's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-0.39.

NeuroPace Accounts Receivable Historical Data

The historical data trend for NeuroPace's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroPace Accounts Receivable Chart

NeuroPace Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

6.02

8.40

7.09

7.48

12.31

NeuroPace Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial													9.19	10.88	11.28	12.31	11.63

NeuroPace Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

NeuroPace Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

NeuroPace's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	11.631	/	18.124	*	91
=	58.56

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), NeuroPace's accounts receivable are only considered to be worth 75% of book value:

NeuroPace's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(58.945	+	0.75 * 11.631	+	0.5 * 11.416	-	84.512
-	0	-	0)	/	28.7174
=	-0.39

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

NeuroPace Accounts Receivable Related Terms

Thank you for viewing the detailed overview of NeuroPace's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroPace (NeuroPace) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroPace Inc (NAS:NPCE) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

455 N. Bernardo Avenue, Mountain View, CA, USA, 94043

Website

https://www.neuropace.com

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.

Executives

Martha Morrell	officer: Chief Medical officer	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Kck Ltd.	10 percent owner	CRAIGMUIR CHAMBERS, ROAD TOWN, TORTOLA D8 VG1110
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Joel Becker	director, officer: Chief Executive Officer	ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Uri Geiger	director	221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Partners Ii L.p.	10 percent owner	2875 NE 191ST, SUITE 500, AVENTURA FL 33180
Irina Ridley	officer: General Counsel and Secretary	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Lisa Andrade	director	6300 BEE CAVE ROAD, BLDG 2, SUITE 100, AUSTIN TX 78746
Greg Shaw Garfield	director	C/O SEMLER SCIENTIFIC, INC., 2330 NW EVERETT ST., PORTLAND OR 97210
Frank M Fischer	director	9701 JERONIMO, IRVINE CA 92618
Evan Norton	director	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Joseph Lacob	director	2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Renee Ryan	director	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Michael Favet	director, officer: Chief Executive Officer	C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043